Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
The question of whether an LHRH antagonist (such as degarelix) is really a better first-line hormone therapy than an LHRH agonist (e.g., leuprolide acetate) is still not fully answered.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, agonist, androgen deprivation, antagonist, Degarelix, leuprolide, LHRH | Leave a Comment »
The idea that one’s diet may affect one’s risk for prostate cancer in general — or perhaps for one’s risk of more aggressive forms of prostate cancer — is not exactly new.
Filed under: Diagnosis, Prevention, Risk | Tagged: aggressive, carotenoid, Diagnosis, diet, glycemic index, leafy, risk, vegetables | 3 Comments »
Men with locally recurrent prostate cancer after first-line external beam radiation therapy (EBRT) have historically had three options for second-line treatment: salvage radical prostatectomy, salvage cryoablation, and salvage brachytherapy.
Filed under: Management, Treatment | Tagged: EBRT, external beam radiation therapy, HIFU, high-intensity focused ultrasound, QOL, quality of life, salvage | Leave a Comment »
A new online dating service has been developed for people who – for medical or other reasons — are unable to participate in sexual intercourse but still want to be able to build meaningful long-term relationships.
Filed under: Living with Prostate Cancer | Tagged: 2date4love, dating, sexual activity | Leave a Comment »
A new paper just published in PLoS ONE describes a development-stage drug known as galiellalactone and how it acts to inhibit the growth of stem cell-like aldehyde dehydrogenase (LLDH)-positive prostate cancer cells.
Filed under: Drugs in development | Tagged: aldehyde dehydrogenase, galiellalactone, stem cell | Leave a Comment »
A recently published report of a Phase II clinical trial conducted by the Eastern Cooperative Oncology Group (ECOG) suggests that the tyrosine kinase inhibitor (TKI) lapatinib (Tykerb) may have clinically significant effects in the treatment of men with progressive prostate cancer after first-line therapy.
Filed under: Drugs in development, Management, Treatment | Tagged: lapatinib | 3 Comments »
A new report giving preliminary data on the clinical performance of novel, urine-based prostate cancer assay uses a method known as prostate-specific antigen/solvent interaction analysis (PSA/SIA) to detect the ratios of different types of PSA (PSA “isoforms”) in the urine of men beleived to be at risk for prostate cancer.
Filed under: Diagnosis, Management, Risk | Tagged: biopsy, Diagnosis, isoform, PSA, PSA/SIA, risk, solvent, urine | 2 Comments »
A new French study has attempted to provide a better appreciation of the effect of predictive factors on the biochemical recurrence-free and overall survival of patients with high-risk prostate cancer after a radical prostatectomy (RP).
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: high, outcome, prediction, radical prostatectomy, risk | 4 Comments »
In 1989 the Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) started randomizing men with a clinically initiated diagnosis of localized prostate cancer to either watchful waiting or open radical prostatectomy as their primary treatment. A new paper has now addressed the long-term quality of life (QoL) of men in this study.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: adverse effects, outcome, quality of life, radical prostatectomy, Scandinavian, SPCG-4, trial, watchful waiting | Leave a Comment »
The potential of high-intensity focused ultrasound (HIFU) as a form of focal therapy for treatment of cancer isolated to a portion of the prostate as opposed to treatment of the entire prostate has been recognized for a considerable period of time. However, limited data are available so far on the outcomes of men treated with [...]
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: complication, focal, HIFU, high-intensity focused ultrasound, outcome, recurrence | 5 Comments »
Back in 2008, we commented on a British report that taller men might be at greater risk than average for prostate cancer in general and for more aggressive forms of prostate cancer in particular. Now a new study based on US patients has again suggested that there may be something to the second of these two [...]
Filed under: Diagnosis, Risk | 5 Comments »
There are no absolute guidelines as to which patients who have positive surgical margins after a radical prostatectomy (RP) are most appropriate for immediate adjuvant radiation therapy (with or without neoadjuvant and/or adjuvant hormone therapy).
Filed under: Management, Treatment | Tagged: adjuvant, margin, outcome, positive, radiation, radical prostatectomy | 3 Comments »
No currently known biomarker can accurately predict the risk of prostate cancer recurrence at the time of or immediately following first-line treatment for localized prostate cancer. The best we can currently manage is to track a patient’s PSA level and his PSA doubling time.
Filed under: Living with Prostate Cancer, Management | Tagged: miRNA, mitochondrial, prognosis, recurrence, RNA | 3 Comments »
As reported last Friday on the Medscape web site, the American Society for Clinical Oncology (ASCO) has recently issued a new policy statement addressing the opportunities presented by the Patient Protection and Affordable Care Act (PPACA) to reduce the disparities in cancer care.
Filed under: Uncategorized | Tagged: care, disparity | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site